Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During Delta vs Omicron Waves

作者：Margaret K. Doll, Alpana Waghmare, Antje Heit, Brianna Levenson Shakoor, Louise E. Kimball, Nina Ozbek, Rachel Blazevic, Larry Mose, Jim Boonyaratanakornkit, Terry Stevens‐Ayers, Kevin Cornell, Benjamin D. Sheppard, Emma Hampson, Faria Sharmin, Benjamin Goodwin, Jennifer M. Dan, Tom Archie, Terry O’Connor, David Heckerman, Frank Schmitz, Michael Boeckh, Shane Crotty · 发表于：JAMA Network Open · 年份：2023 · DOI：10.1001/jamanetworkopen.2023.1181 · 被引用次数：22 · 研究领域：SARS-CoV-2 and COVID-19 Research、Long-Term Effects of COVID-19、COVID-19 Clinical Research Studies

Importance: The US arrival of the Omicron variant led to a rapid increase in SARS-CoV-2 infections. While numerous studies report characteristics of Omicron infections among vaccinated individuals or persons with previous infection, comprehensive data describing infections among adults who are immunologically naive are lacking. Objectives: To examine COVID-19 acute and postacute clinical outcomes among a well-characterized cohort of unvaccinated and previously uninfected adults who contracted SARS-CoV-2 during the Omicron (BA.1/BA.2) surge, and to compare outcomes with infections that occurred during the Delta wave. Design, Setting, and Participants: This prospective multisite cohort study included community-dwelling adults undergoing high-resolution symptom and virologic monitoring in 8 US states between June 2021 and September 2022. Unvaccinated adults aged 30 to less than 65 years without an immunological history of SARS-CoV-2 who were at high risk of infection were recruited. Participants were followed for up to 48 weeks, submitting regular COVID-19 symptom surveys and nasal swabs for SARS-CoV-2 polymerase chain reaction (PCR) testing. Data were analyzed from May to October 2022. Exposures: Omicron (BA.1/BA.2 lineages) vs Delta SARS-CoV-2 infection, defined as a positive PCR test result that occurred during a period when the variant represented at least 50% of circulating SARS-CoV-2 variants in the participant's geographic region. Main Outcomes and Measure(s): The main ou...